Rhenman & Partners Asset Management Ab Cassava Sciences Inc Transaction History

Rhenman & Partners Asset Management Ab

  • $1.2 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022
SELL
$36.77 - $90.91 $3.13 Million - $7.73 Million
-85,000 Closed
0 $0
Q3 2021

Nov 12, 2021
SELL
$41.79 - $135.3 $1.25 Million - $4.06 Million
-30,000 Reduced 26.09%
85,000 $5.28 Million
Q2 2021

Aug 13, 2021
BUY
$32.15 - $89.72 $3.7 Million - $10.3 Million
115,000 New
115,000 $9.83 Million

Others Institutions Holding SAVA

# of Institutions
207
Shares Held
14M
Call Options Held
2.98M
Put Options Held
6.57M
View Full List

About CASSAVA SCIENCES INC

SAVA Quotes by TradingView
  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $107M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email